Vaccine 411 - tracking the race to find a vaccine for the Coronavirus Covid 19

<p><strong>Vaccine 411 061620</strong></p><p>This is Vaccine 4-1-1.&nbsp;&nbsp;As the race for a COVID-19 vaccine continues, here are the numbers:</p><p>143 vaccines are in development, according to The New York Times&nbsp;&nbsp;</p><p>125 are in pre-clinical trials.&nbsp;</p><p>8 are in Phase 1 Clinical Trials.</p><p>8 are in Phase 2.</p><p>2 are in Phase 3.&nbsp;One in the United Kingdom and one in Australia.</p><p>On this episode of Vaccine 411… researchers in Australia hope to re-purpose a tuberculosis vaccine developed in the 1900’s to fight today’s COVID-19.&nbsp;</p><p>First, the news:&nbsp;The FDA has revoked their emergency use authorization for Chloroquine and Hydroxychloroquine to treat COVID-19.&nbsp;Beijing based, Sinovac Biotech, announced their vaccine candidate “CoronaVac” was safe in humans and induced antibodies in more than 90% of candidates.&nbsp;According to statnews.com, they are submitting a design protocol to move to Phase III, that will involve candidates in China and Brazil.&nbsp;Europe’s Inclusive Vaccine Alliance, comprised of France, Germany, Italy and The Netherlands have signed an agreement with AstraZeneca to provide up to 400 million doses of the potential COVID-19 vaccine, reports Reuters.&nbsp;Germany will buy nearly 23% of CureVac, for 340 million dollars.&nbsp;CureVac is one of many companies working on a COVID-19 vaccine.&nbsp;They plan to begin Phase I human trials this month.&nbsp;&nbsp;</p> &#10;&nbsp;<br /><hr><p style='color: grey; font - size: 0.75em; '>See <a style='color: grey; ' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>